Explore the words cloud of the LEONID project. It provides you a very rough idea of what is the project "LEONID" about.
The following table provides information about the project.
Coordinator |
DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA
Organization address contact info |
Coordinator Country | Italy [IT] |
Project website | http://leoniddiatech.blogspot.it |
Total cost | 1˙704˙000 € |
EC max contribution | 1˙704˙000 € (100%) |
Programme |
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
Code Call | H2020-SMEINST-2-2014 |
Funding Scheme | SME-2 |
Starting year | 2015 |
Duration (year-month-day) | from 2015-07-01 to 2016-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA | IT (JESI) | coordinator | 1˙465˙438.00 |
2 | BIMIND SAS DI MARINELLI MARCO VICO MAURIZIO EC | IT (JESI) | participant | 155˙000.00 |
3 | GENETICLAB S.R.L. | IT (Pordenone) | participant | 83˙561.00 |
The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment. The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK. The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility. The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers. For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.
Final event | Documents, reports | 2019-05-30 12:53:27 |
Take a look to the deliverables list in detail: detailed list of LEONID deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEONID" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LEONID" are provided by the European Opendata Portal: CORDIS opendata.
Preventing Respiratory Events through Proactive Assessment of Respiratory Effort
Read MoreDevelopment of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth
Read MoreADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach
Read More